TABLE 3.

MIC distributions for eight β-lactams and ciprofloxacin against 100 clinical isolates of BLPAR H. influenzae

Antimicrobial agent(s)	No. of isolates with MIC (μg/ml):										MIC (μg/ml)			% of isolates susceptiblea
	≤0.12	0.25	0.5	1	2	4	8	16	32	≥64	Range	50%	90%
Ampicillin	0	0	0	0	0	6	94	—b	—	—	4-≥8	≥8	≥8	0
Ampicillin-sulbactam	0	0	9	41	25	17	8	0	0	0	0.5-8	0.25	0.5	75
Amoxicillin-clavulanate	0	9	41	25	20	13	0	0	0	0	0.5-4	0.5	1	100
Piperacillin	0	0	0	1	18	12	14	12	21	22	1->64	16	>64
Piperacillin-tazobactam	99	1	0	0	0	0	0	0	0	0	≤0.03-0.25	≤0.03	0.06	100
Ceftriaxone	97	3	0	0	0	0	0	0	—	—	≤0.008-0.25	≤0.008	0.015	100
Imipenem	13	19	18	18	2	2	1	—	—	—	≤0.12-≥8	1	1	99
Meropenem	95	3	0	0	0	0	0	—	—	—	≤0.12	≤0.12	≤0.12	100
Ciprofloxacin	98	2	0	0	0	—	—	—	—	—	≤0.03-0.25	≤0.03	≤0.03	100

^aCLSI MIC breakpoints (5).

^b—, untested concentration.